Long-term follow-up for cell therapy participants
Part of Cancer clinical trials.
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received at least one dose of an ADP adoptive cell therapy treatment
- You previously finished a related ADP-sponsored or supported treatment study, or you withdrew from it
- If you joined through “managed access” with a GSK cell therapy, you must have completed that treatment too
- You can follow the study’s contraception rules while you’re in the study
- You’re able to understand and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
This trial is for people who have already received a cell or gene therapy in another AstraZeneca study. It simply checks in on your health over time after that treatment.
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.